These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 25511792)

  • 1. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
    Phan-Ba R; Pace A; Calay P; Grodent P; Douchamps F; Hyde R; Hotermans C; Delvaux V; Hansen I; Moonen G; Belachew S
    Neurorehabil Neural Repair; 2011 Sep; 25(7):672-9. PubMed ID: 21436388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?
    Novotna K; Rusz J; Kubala Havrdova E; Lizrova Preiningerova J
    J Neural Transm (Vienna); 2019 Jun; 126(6):731-737. PubMed ID: 31098724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
    Cadavid D; Jurgensen S; Lee S
    PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
    Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
    Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
    Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
    JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the Six-Spot Step Test as a Measure of Walking Performance in Ambulatory Individuals With Multiple Sclerosis.
    Fritz NE; Jiang A; Keller J; Zackowski KM
    Arch Phys Med Rehabil; 2016 Apr; 97(4):507-512. PubMed ID: 26577146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
    Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.
    Larson RD; Larson DJ; Baumgartner TB; White LJ
    Clin Rehabil; 2013 Aug; 27(8):719-23. PubMed ID: 23426567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Motl RW; Cohen JA; Benedict R; Phillips G; LaRocca N; Hudson LD; Rudick R;
    Mult Scler; 2017 Apr; 23(5):704-710. PubMed ID: 28206828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
    Capobianco M; di Sapio A; Malentacchi M; Malucchi S; Matta M; Sperli F; Bertolotto A
    Eur J Neurol; 2015 Mar; 22(3):585-7. PubMed ID: 24995482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.